GSK, Belantamab Mafodotin

Belantamab Mafodotin shows significant overall survival benefit, reducing the risk of death by 42% in multiple myeloma at or after first relapse
Belantamab Mafodotin shows significant OS benefit, reducing the risk of death by 42% in multiple myeloma at or after first relapse
GSK's belantamab mafodotin reduced death risk by 42% in study
GSK (NYSE:GSK) reported that a study showed its drug belantamab mafodotin was able to reduce the risk of death by 42% in patients with multiple myeloma at or after first relapse. The study is evaluating belantamab mafodotin in combination with bortezomib plus dexamethasone,
GSK says median overall survival not reached in multiple myeloma study
GSK (GSK) announced “statistically significant and clinically meaningful” overall survival results from a planned interim analysis of the
Blenrep Combination Reduces Death Risk by 42% in Relapsed Multiple Myeloma
The DREAMM-7 trial shows belantamab mafodotin combined with bortezomib and dexamethasone significantly improves overall survival in relapsed or refractory multiple myeloma, reducing death risk by 42% compared to standard therapy.
GSK drug cut death risk by 42% in multiple myeloma study
GSK (GSK) reported a study showed its drug belantamab mafodotin was able to reduce the risk of death by 42% in certain patients with multiple myeloma. Read more here.
GSK drug shows promise in multiple myeloma
A trial has shown that belantamab mafodotin can reduce the risk of death by 42% in patients with relapsed or refractory multiple myeloma.
GSK's drug combo shown to cut risk of death by 42% in type of blood cancer
British drugmaker GSK said on Monday its experimental cancer drug Blenrep in combination with other treatments reduced the risk of death by 42% in multiple myeloma, a common type of blood cancer, at or after first relapse compared to an existing treatment.
Boost for GSK as new bone marrow cancer drug drastically cuts risk of death in patients
The results will be welcomed by boss Emma Walmsley (pictured), who has been trying to improve the pipeline of new drugs and vaccines.
Medpage Today on MSN1d
Pulled Myeloma Drug Improves Survival in Trial
A significant overall survival (OS) benefit with belantamab mafodotin (belantamab; Blenrep) in a phase III trial of relapsed ...
Oncology Nurse Advisor1d
Could a Belantamab Mafodotin Combo Be a New Standard for Rel/Ref MM?
Updated results from the DREAMM-7 trial support the use of belantamab mafodotin plus bortezomib and dexamethasone “as a potential new standard of care,” according to Vania Hungria, MD, PhD.
Medscape2d
Eye Toxicities Are a Growing Concern With Certain ADCs
Some antibody-drug conjugates may cause such significant ocular toxicity that patients have vision damage or have to stop ...
The American Journal of Managed Care24d
OS Better With Belantamab Mafodotin Triplet vs Daratumumab in R/R MM
The DREAMM-7 trial showed belantamab mafodotin combination significantly improved overall survival in relapsed/refractory multiple myeloma compared to daratumumab-based therapy. The ...
Daily2d
Blenrep combo accepted for priority review in China in relapsed/refractory multiple myeloma: GSK
London: GSK plc has announced that the National Medical Products Administration (NMPA) of China has accepted for review a new ...
pharmaphorum3d
ASH: Blenrep ups survival by 42% in multiple myeloma trial
The data reported at ASH revealed a 74% OS rate in the Blenrep plus BorDex (BVd) arm of DREAMM-7 versus a 60% rate with ...